2310044G17Rik Activators
RIKEN cDNA 2310044G17 gene product activators consist of a collection of chemical compounds that enhance the protein's function through various signaling cascades and cellular processes. Forskolin, by increasing intracellular cyclic AMP (cAMP), indirectly enhances RIKEN cDNA 2310044G17 gene product activity through the activation of protein kinase A (PKA), which can phosphorylate substrates affecting the protein's state and function. Concurrently, IBMX serves to elevate cAMP levels by inhibiting their degradation, thereby prolonging PKA's action and potentially enhancing the activity of the RIKEN cDNA 2310044G17 gene product. Similarly, Epigallocatechin gallate (EGCG) modulates kinase signaling pathways, which can lead to altered phosphorylation states and enhancement of the RIKEN cDNA 2310044G17 gene product. PMA and Sphingosine-1-phosphate activate PKC and G-protein-coupled receptors, respectively, initiating phosphorylation events that may enhance the protein's activity. The PI3K inhibitor LY294002 could pivot signaling through Akt to favor phosphorylation patterns that enhance the RIKEN cDNA 2310044G17 gene product, while Staurosporine, a kinase inhibitor, could activate compensatory pathways that indirectly upregulate the protein's activity.
Inhibition of specific kinases also plays a role in the activation of RIKEN cDNA 2310044G17 gene product. U0126 and SB203580 inhibit MEK1/2 and p38 MAPK, respectively, promoting a shift in signaling that may enhance the activity of the protein by modulating phosphorylation. Genistein, by inhibiting tyrosine kinase activity, could lead to reduced competitive phosphorylation, indirectly enhancing RIKEN cDNA 2310044G17 gene product's function. Thapsigargin and A23187 both increase intracellular calcium levels, but through different mechanisms: Thapsigargin inhibits Ca2+ ATPase in the sarcoplasmic/endoplasmic reticulum, and A23187 acts as a calcium ionophore. The resultant calcium signaling can activate calcium-dependent kinases, leading to the phosphorylation and functional enhancement of the RIKEN cDNA 2310044G17 gene product through post-translational modifications, contributing to the intricate network of signaling that dictates the activity state of this protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX acts as a nonspecific inhibitor of phosphodiesterases, preventing cAMP degradation, thereby sustaining PKA activation which could enhance the phosphorylation and activity of the RIKEN cDNA 2310044G17 gene product. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is a potent antioxidant that modulates kinase signaling pathways. It can modify the phosphorylation state of proteins and thus could enhance the activity of RIKEN cDNA 2310044G17 gene product through altered signal transduction. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate a variety of proteins. PKC mediated phosphorylation may enhance the activity of the RIKEN cDNA 2310044G17 gene product by modulating its interaction with other cellular components. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
S1P binds to its G-protein-coupled receptors, initiating a signaling cascade that can lead to the activation of various kinases. This signaling could enhance the activity of the RIKEN cDNA 2310044G17 gene product through post-translational modifications. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3K. By inhibiting PI3K, it alters downstream signaling pathways such as Akt, potentially leading to an indirect enhancement of RIKEN cDNA 2310044G17 gene product activity through changes in phosphorylation patterns. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent kinase inhibitor with a broad spectrum of targets. By selectively inhibiting certain kinases, it could lead to the activation of compensatory pathways that indirectly enhance the activity of RIKEN cDNA 2310044G17 gene product. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. By inhibiting this kinase, it could indirectly enhance the activity of RIKEN cDNA 2310044G17 gene product through the modulation of stress-activated protein kinase signaling pathways. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor, which may enhance the activity of RIKEN cDNA 2310044G17 gene product by reducing competitive phosphorylation by other tyrosine kinases and changing the cellular signaling landscape. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin raises intracellular calcium levels by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA). Increased calcium can activate calcium-dependent kinases, which might indirectly enhance the activity of RIKEN cDNA 2310044G17 gene product. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 acts as a calcium ionophore, transporting Ca2+ across cell membranes. Elevated intracellular calcium levels could activate signaling pathways that indirectly enhance the activity of RIKEN cDNA 2310044G17 gene product through phosphorylation and other post-translational modifications. | ||||||